Endocrine Research

Endocrine Research is a quarterly peer-reviewed journal published by Taylor & Francis for laboratory and clinical work on hormones, and its 2025 Journal Impact Factor stands at 1.9.《内分泌研究》（Endocrine Research）由 Taylor & Francis 按季出版，刊载激素相关的实验室与临床研究，2025 年期刊影响因子为 1.9。

Papers range from receptor pharmacology and assay development to small clinical cohorts, and the present title has carried that remit since 1984, when it took over a volume sequence begun ten years earlier.稿件从受体药理学与测定方法开发，一直延伸到小规模临床队列，现名自 1984 年启用，承接了十年前开始的卷号序列。

Scope

• The declared remit is endocrinology in its broadest context, and receptors together with the mechanism of action of hormones head the list of subjects of interest.公开申明的范围是广义内分泌学，激素受体与激素作用机制在感兴趣主题的清单上列于首位。
• Methodological advances in the detection and measurement of hormones form the second declared area, which keeps assay chemistry and immunoassay design inside the journal's remit.激素检测与测定方法学的进展是第二块申明领域，测定化学与免疫分析设计因此留在收录范围之内。
• The structure and chemical properties of hormones make up the third listed topic, so work on steroid chemistry or peptide conformation shares pages with clinical reports.激素的结构与化学性质构成第三项列明主题，类固醇化学或肽构象的工作与临床报告共处同一版面。
• Thyroid disease supplies a steady share of content, and Graves' disease, Hashimoto thyroiditis, subacute thyroiditis and medullary thyroid carcinoma all appear in recent volumes.甲状腺疾病提供稳定的稿源，Graves 病、桥本甲状腺炎、亚急性甲状腺炎以及甲状腺髓样癌在近几卷均有刊载。
• Diabetes research runs from monogenic forms and islet cell autophagy to diabetic kidney disease, continuous glucose monitoring and ketoacidosis among dialysis patients.糖尿病研究从单基因类型与胰岛细胞自噬，延伸到糖尿病肾病、持续葡萄糖监测以及透析患者的酮症酸中毒。
• Pituitary and neuroendocrine papers cover prolactinomas, acromegaly, Cushing syndrome and the desmopressin stimulation test used to separate ACTH-dependent causes.垂体与神经内分泌稿件涉及催乳素瘤、肢端肥大症、库欣综合征，以及用于区分 ACTH 依赖病因的去氨加压素兴奋试验。
• Adrenal work arrives through adrenocortical carcinoma series and mitotane toxicity reports, which shows that rare tumour cohorts are welcome despite the small annual output.肾上腺方向可见肾上腺皮质癌系列与米托坦毒性报告，年发文量虽小，罕见肿瘤队列仍受欢迎。
• Reproductive endocrinology spans polycystic ovary syndrome, neuropeptide measurements in euthyroid women, menopause, male hypogonadism and gender-affirming hormone therapy.生殖内分泌覆盖多囊卵巢综合征、甲状腺功能正常女性的神经肽测定、绝经、男性性腺功能减退以及性别肯定激素治疗。
• Bone and mineral metabolism appears in osteoporosis experiments on ovariectomised rats, bone density changes after exercise, and paediatric hypoparathyroidism with inactivating PTH receptor signalling.骨与矿物质代谢见于去卵巢大鼠的骨质疏松实验、运动后的骨密度变化，以及伴 PTH 受体信号失活缺陷的儿童甲状旁腺功能减退。
• Obesity and energy metabolism enter through visceral adiposity, lipidomic and metabolomic profiling, weight loss after bariatric surgery and carbohydrate-restricted diets in type 2 diabetes.肥胖与能量代谢经由内脏脂肪、脂质组与代谢组分析、减重手术后的体重下降以及 2 型糖尿病的低碳水饮食进入版面。
• Hormone-cardiovascular links recur, with serum testosterone and atherosclerotic risk, the cortisol rhythm and nocturnal glycaemia, and finerenone in diabetic heart failure among recent titles.激素与心血管的关联反复出现，近期题目包括血清睾酮与动脉粥样硬化风险、皮质醇节律与夜间血糖，以及非奈利酮用于糖尿病合并心力衰竭。
• Analytical papers validate drug assays and candidate biomarkers, such as a lenvatinib assay and circulating progastrin-releasing peptide in neuroendocrine neoplasms.分析类论文验证药物测定与候选生物标志物，例如仑伐替尼测定以及神经内分泌肿瘤中的循环胃泌素释放肽前体。
• Two article types are named in the guidance, original articles and brief reviews, and the reviews reach print by invitation rather than through unsolicited submission.投稿说明列明两类稿件，原创论文与简报式综述，其中综述由编辑部约请，不走自由投稿的通道。

History

• The title began life as Endocrine Research Communications, whose first volume appeared in 1974 from Marcel Dekker in New York and whose last, volume 9, came out in 1982.该刊最初名为 Endocrine Research Communications，1974 年由纽约的 Marcel Dekker 推出第 1 卷，末卷为 1982 年的第 9 卷。
• When the present name was adopted in 1984 the numbering did not restart, and the first issue under it is volume 10, number 1 of that year.1984 年改用现名时卷号并未重新起算，新刊名下的第 1 期就是当年的第 10 卷第 1 号。
• Volume 10, number 1 also marks where Index Medicus and later MEDLINE began covering the title, as the National Library of Medicine records in its catalogue.第 10 卷第 1 号也是 Index Medicus 与后来 MEDLINE 的收录起点，美国国家医学图书馆的著录这样记载。
• The early volumes were thin and irregular in issue count, with volume 10 closing in a combined 3-4 and volume 11 split into two double issues.早期各卷篇幅不大，期号也不齐整，第 10 卷以合刊的第 3 至 4 期收尾，第 11 卷拆成两个双期。
• The first issue of the new title carried a notice headed Change in Editorial Staff, marking the point at which the board was rebuilt around the new name.新刊名的首期刊出一则题为 Change in Editorial Staff 的启事，标明编委会围绕新名号完成重建。
• Dekker's New York imprint gave way to Informa Healthcare in London, and the National Library of Medicine keeps both addresses, the older as original and the newer as current.Dekker 在纽约的出版印记后来让位于伦敦的 Informa Healthcare，美国国家医学图书馆把两处地址都保存下来，旧的标为原址，新的标为现址。
• The DOI prefix moved with the platform, from 10.3109 on Dekker-era records to 10.1080 on papers published under Taylor & Francis.DOI 前缀随平台更替，Dekker 时期的记录用 10.3109，Taylor & Francis 旗下发表的论文改用 10.1080。
• One volume now covers a calendar year and carries four numbered issues, so volume 47 belongs to 2022, volume 50 to 2025 and volume 51 to 2026.如今一卷对应一个日历年，卷内编四个期，第 47 卷属于 2022 年，第 50 卷属于 2025 年，第 51 卷属于 2026 年。
• The predecessor's early volumes carried six to eight issues a year, and that frequency contracted once the title shortened and the quarterly rhythm settled.前身刊早期一年出六至八期，刊名缩短之后期数收缩，季度节奏逐渐固定。
• Selection for the Science Citation Index Expanded placed the title in ENDOCRINOLOGY & METABOLISM, where the 2025 release ranks it 154th of 198 journals in the fourth quartile.入选 Science Citation Index Expanded 之后，该刊归入 ENDOCRINOLOGY & METABOLISM 类目，2025 年榜单在 198 种刊物中把它排在第 154 位，属第四分位。
• The 2025 Journal Impact Factor reads 1.9, the five-year figure 1.7 and the Journal Citation Indicator 0.4, against 766 citations in total and a cited half-life of ten years.2025 年期刊影响因子为 1.9，五年影响因子为 1.7，期刊引文指标为 0.4，总被引 766 次，被引半衰期为十年。
• Five annual values moved between 1.72 in 2021, 2.306 in 2022, 1.5 in 2023, 1.8 in 2024 and 1.9 in 2025, a band narrow enough to suggest a settled readership.五年间的影响因子依次为 2021 年的 1.72，2022 年的 2.306，2023 年的 1.5，2024 年的 1.8，2025 年的 1.9，波动幅度有限，读者群显得稳定。
• Access follows a hybrid model, so authors may pay for open publication while the subscription route stays open, and gold open access held 2.9 percent of 2025 content.该刊采用混合模式，作者可付费开放发表，订阅通路同时保留，2025 年内容中金色开放获取占 2.9%。
• Output is small, roughly sixteen articles a year in the 2025 dataset, which keeps the journal closer to a specialist quarterly than to a high-volume clinical title.年发文量偏小，2025 年数据集约为每年 16 篇，更接近专门化的季刊，而非高产量的临床刊物。

Editors

• Review policy is stated plainly, since invitations to submit brief reviews are issued to specific authors by the editors and unsolicited review proposals are not invited.综述方面的方针写得直白，简报式综述由编辑部向特定作者发出邀请，自由来稿的综述提案不在约请之列。
• Original research fills the issues, and the contents of volume 50 consist almost entirely of articles, from receptor pharmacology through to single-centre patient series.原创研究占满各期，第 50 卷的篇目几乎全是论文，从受体药理学一直到单中心病例系列。
• The board roster is printed as front matter closing a volume, and the page appears at the end of volumes 41 and 42 under the heading Editorial Board Page.编委会名单以卷末附页印出，第 41 卷与第 42 卷的卷尾都有一页题为 Editorial Board Page 的名单。
• Manuscripts enter through ScholarOne Manuscripts at mc.manuscriptcentral.com/lerc, the separate submission site opened for this title rather than a shared editorial mailbox.稿件经地址为 mc.manuscriptcentral.com/lerc 的 ScholarOne 系统投递，这是为这本刊单独开设的入口，并非共用的编辑信箱。
• Production runs continuously, so an accepted paper receives a DOI and appears online before an issue is assigned, as the 2026 records without a volume number show.生产流程连续运转，录用的论文先取得 DOI 并在线发布，随后才编入期号，2026 年那些没有卷号的记录即为例证。
• Corrections travel as items in their own right, and a Correction sits beside research papers in volume 51, number 2.更正以独立条目发布，第 51 卷第 2 期里就有一条更正摆放在研究论文之间。
• Small studies are admitted, and pilot assays, single-centre retrospective cohorts and short observational series all reached print in recent volumes.小规模研究可以进入版面，预试验测定、单中心回顾队列与短篇观察系列在近几卷都得到刊载。
• Narrative reviews appear next to commissioned brief reviews, and a 2026 review of trigeminal involvement in pancreatic innervation shows that speculative synthesis is welcome.叙述性综述与约稿的简报式综述并存，2026 年一篇讨论三叉神经参与胰腺支配的综述说明推测性的整合文章也能通过。
• The journal keeps a memorial voice, and a 2022 editorial reminiscence marked the death of Robert I. Gregerman (1930-2021) inside volume 47.该刊保留纪念性的声音，2022 年一篇编辑回忆文章在第 47 卷的版面上追念（Robert I. Gregerman，1930 至 2021）。
• Correspondence about a manuscript travels through the publisher's platform, and the National Library of Medicine records the imprint as London rather than New York, where the older address belongs.稿件往来经出版方平台运转，美国国家医学图书馆著录的出版地是伦敦，纽约那处地址属于更早的年代。